WorkflowAPI & Drug Substance

Nitrosamine Risk Assessment

A nitrosamine risk assessment solution for multi-product drug substance plants. It draws each product's route and each shared solvent, vessel and water line on one map, then works the limit wherever an amine can meet a nitrosating source.

Follow the toluene path from map to client letter ↓
Watch with transcript →
The problem

Low risk on paper, and a wash solvent recovered after another product's quench

Assessments are written one active at a time, from the route as filed and a stack of supplier questionnaires. In a multi-product API plant the toluene, the filter-dryer and the purified water are shared, and a solvent recovered from one product's mother liquors can end up washing another product's cake. Neither product's assessment owns that path.

Then a change control lets recovered solvent into a wash step. Its risk section checks purity and water, calls the nitrosamine question same solvent, and passes as minor. Batches are made and shipped for months while the old assessment still says no nitrosating agent, until a periodic review, the client's own testing or an inspector asks where the solvent came from.

Built forNitrosamine risk assessorsPlant QA headsQC laboratory headsRegulatory CMC leads

The Problem Today

Every active gets its own assessment, so a solvent recovered from one product and reused in another belongs to none of them.

Aug 2025
FDA's date to finish NDSRI testing and submit the changes published
10%
of the acceptable intake: above it, each batch is tested published

Stitched together by hand

  • Routes
  • Solvent log
  • Changes
  • Limits
  • Reopened only at periodic reviewA minor solvent change asks no nitrosamine question
  • One ring rule misreadA wrong potency feature loosens the limit almost fourfold

The Solution

  1. Lanes crossed by shared linesOne lane per active; recovered solvent, vessels and water run across
  2. Change controls reopen itEach change since the last assessment is screened against the map
  3. Scored, then challengedPotency worked rule by rule, then attacked as an agency would
  4. Held now, signed by QAShared material stops at once; the plan and letter carry signatures

Built-in controls

  • A hold lifts only on accepted results and a change in place
  • The person who prepares an assessment never approves it
  • Suppliers and the lab answer in fields, read by people

What You Get

The client hears from its API maker first, with each limit, its source and the test plan in one signed letter.

  • A map the next product reusesA new transfer starts from crossings already drawn
  • New assessors score like veteransEach potency rule and the agency's likely questions on screen
  • Limits an inspector can traceEach figure tied to its guidance section and plant record
Features

Nitrosamine risk assessment for four actives on one solvent recovery unit

The assessor runs the read and confirms the score; QC and QA sign the test plan; the QA head reads both holds, then signs the letter.

demoThe plant, its clients, suppliers, people, batches and change controls are sample data, as is each figure on these screens.

  1. 01Crossroads map

    Nitrosamine crossroads map of a multi-product API plant, drawn by agents

    • One lane per product, stages in order. The assessor sees where four actives share the solvent recovery unit, a filter-dryer, purified water and two reagents.
    • Amine and nitrosating sources marked per stage. Round and square markers are read off each master production instruction, so a secondary amine and a nitrite quench are read side by side.
    • The plan, sources and confidence of each agent. The assessor sees why the read reached each finding and can open the record it rests on.
  2. 02Credible crossing

    Recovered solvent traced from a nitrite quench into another product's wash

    • The path drawn stage to stage. Risk that moves from one product into another shows up where it crosses, so it no longer falls between two assessments.
    • What could form, with its records. The drug-related nitrosamine, NDMA and NDEA are listed with their limits, and the solvent log and the approving change control open from that panel.
  3. 03Limits

    Nitrosamine acceptable intake limits in ppm at the client's daily dose

    • Acceptable intake over maximum daily dose. Each sum is printed as worked, with its guidance section, so the QA head reviews the worked division rather than a spreadsheet cell.
    • The control trigger beside the planned LOQ. The QC lab sees at once whether each planned method can quantify at a tenth of its limit.
    • The total rule when several can form. The total limit sits beside the single ones, held to the most potent or to shares of each limit summing to 100% at most.
  4. 04CPCA score

    CPCA potency category for an NDSRI, scored feature by feature

    • Each scoring-table feature with its rule. A new assessor follows the alpha-hydrogen count and each deactivating feature, and a reviewer sees which row moved the category.
    • Confirmed only after the structure is read. The category counts once the assessor has opened the structure notes and the guidance and signed, with the previous assessment alongside.
  5. 05Agency assessor

    An agency assessor agent attacks the draft and catches a misread ring rule

    • Challenged as an agency reviewer would. A purge argument with no data behind it goes into the test plan instead of into the assessment.
    • Its own agents' errors included. The agents' own misread ring rule is caught before anyone signs a limit almost four times too loose.
    • Each point with an owner. A point is answered by an agent, fixed in the draft, or handed by name to the MSAT lead, the assessor or the QA head.
  6. 06Holds

    Recovered solvent and unshipped batches held at once, read by QA after

    • A hold that acts before a signature. Under a setting signed off by the QA head, the shared solvent is stopped before the next wash charge can draw it, and the step it blocks is named.
    • Lifting waits for results and a change in place. Nobody lifts a hold they placed, and the QA head lifts one only on accepted results, an approved assessment and an implemented change.
  7. 07What-if

    Fresh solvent, a dedicated line or lot testing, and a doubled dose compared

    • Options costed from inputs anyone can edit. The assessor proposes one change with its cost, timing and risk in view; the QA head decides on it inside the assessment.
    • A doubled daily dose played forward. At 240 mg/day each limit halves and the NDEA method is just within its tenth, so the lab sees the margin before a label changes.
    • Testing in place of removal, flagged. Keeping the shared line and testing each recovered lot is marked as still against FDA's same-process recommendation.
  8. 08Test plan

    Nitrosamine confirmatory testing plan with batches before and after the change

    • Batches chosen around the change. One retained batch from before the solvent change and three from after give the comparison a reviewer looks for.
    • Method needs, then the plan. The QC lab head opens the method summary before signing; QA approval follows only once the change control has been read.
  9. 09Client letter

    Client notification letter with each sentence matched to its record

    • A record tag on each sentence. A line with no data behind it is marked, so the QA head knows which words rest on judgment alone.
    • Signed only after the score and the plan. The client hears of the risk from its API maker inside the agreed days, and only once the category is confirmed and the plan approved.

A score, a plan, two holds and a letter, each signed by someone else

Four people share one assessment; nobody approves their own part.

Nitrosamine risk assessors

Each active's assessment, the plant map, holds and supplier questionnaires

  • Change controls screened as they arrive
  • A potency score with each rule shown
  • Holds placed when a crossing turns credible
Plant QA heads

Approve test plans and assessments, read holds, sign what goes to clients

  • Each sum and source one click away
  • No hold that goes unread
  • No letter on an unconfirmed score
QC laboratory heads

Method needs, contract-lab requests and the certificate when it returns

  • Each LOQ checked against a tenth of its limit
  • A lab request built from the plan
  • Results taken in by field
Regulatory CMC leads

The drug master file and what it says the plant does

  • A hand-off when the wash solvent changes
  • The proposed option attached
  • The annual report date in view

The potency scorer applies no category until a person confirms it

Eight agents read, trace, score and draft; people confirm, approve and sign.

Route reader

Reads each master production instruction and marks the amines and nitrosating sources on each stage.

  • Never claims a purge without data
Shared-asset tracer

Reads the recovered-solvent, equipment and water records and draws who shares what.

  • Treats no line as dedicated without the log
Change-control reader

Screens each change control since each product's last assessment and reopens a crossing it touches.

  • Never closes or approves a change control
CPCA scorer

Scores each possible drug-related nitrosamine feature by feature from the published tables.

  • Applies no score a person has not confirmed
Limit calculator

Divides each acceptable intake by the daily dose and works the tenths, totals and what-if doses.

  • Uses the client's labeled dose unless a person changes it
Test planner

Chooses batches and analytes, checks each LOQ and drafts the contract-lab request.

  • Sends nothing before QC and QA have both signed
Letter and questionnaire drafter

Drafts supplier questionnaires, the client letter and the master-file hand-off.

  • Sends nothing outside unsigned
  • Passes typed replies to a person
Agency assessor

Attacks the score and draft as an inspecting agency's assessor would.

  • Settles none of the points it raises
More screens

The change control that opened the path checked purity and water, nothing more

Past the crossing: the record that started it, the suppliers, the waiting draft, the changes left for a person, the client's view and the trail.

The question the change skippedSection 4 checked purity, water and residual THF, then answered the nitrosamine question with same solvent, same grade, silent on where the toluene was recovered.
Two suppliers, answered in fieldsThe reagent supplier has yet to state diethylamine in its triethylamine; the DMF supplier answered dimethylamine, nitrite and recovered content field by field.
A draft in FDA's three steps that waitsThe three steps are filled in, and the draft lists what still blocks preparing it: four assessor points, four change controls and one supplier answer.
Four change controls for a personA second triethylamine source, a water resin, a second activated carbon and a longer storage period wait for the assessor to open each record and settle it.
What the client's regulatory lead seesThe signed letter on the client's portal, with two fields still to answer: whether its drug product assessment will be updated, and the daily dose it confirms.
Signatures, with what each one meantScore confirmed, option A proposed, hold placed, plan signed by two, both holds read and the letter sent, each row with its signature meaning, session and any reason given.

demoSample data, from the working solution.

Only the QA head lifts a hold, and never a hold the QA head placed

Confirming a potency categoryThe assessor confirms it after reading the structure and the guidance; the QA head approves it inside the assessment.
Lifting a holdOnly the QA head lifts one, never their own, and only on accepted results, an approved assessment and a change recorded as implemented.
Sending outside the plantQuestionnaires, the lab request and the client letter leave only under a person's signature; a typed note needs a second reader.
Deciding about the client's productBatches already at the client's drug product maker, and release to market, are the client's own quality and regulatory calls.

Production instructions, the solvent log and the guidance behind each limit

Master production instructionsEach active's route, stage by stage, with its reagents, quenches and solvents.
Solvent, equipment and water recordsWhich recovered lots went where, who shares each vessel, and nitrite on the water loop.
Change controlsEach one raised since each product's last assessment, with its risk section.
Supplier questionnaires and certificatesAmine and nitrite content of reagents and solvents, as each supplier states it.
FDA nitrosamine guidance and acceptable intakesThe control guidance, published limits and potency tables, with the client's labeled dose.

What QA heads ask about nitrosamine risk assessment

What is a nitrosamine risk assessment?

A nitrosamine risk assessment is the first of FDA's three steps for nitrosamine impurities: find where an amine and a nitrosating source can meet in the route, the materials and the shared plant, then decide what to test and change. Here agents draw that across the whole plant and keep it open as change controls arrive.

How is an NDSRI limit set when FDA lists no limit for that compound?

The potency category comes from the categorization approach in FDA's guidance on acceptable intake limits for drug substance-related impurities. The scorer shows each feature and rule, a person confirms the category, and the limit in parts per million is the acceptable intake divided by the client's maximum daily dose.

Does recovered solvent need its own place in the assessment?

FDA recommends reusing recovered material only in the same or an earlier step of the process it came from. The shared-asset tracer reads the solvent log, so a solvent recovered from one product and used in another opens a crossing on both.

When does a nitrosamine need testing on each batch?

Under FDA's guidance, a nitrosamine found above one tenth of its acceptable intake limit is tested on release. The limits screen puts that tenth beside each planned LOQ before the plan is signed.

Who signs the client letter, and who decides about batches already shipped?

The plant's QA head signs it, after opening the quality agreement and only once the potency category is confirmed and the test plan approved. Batches already at the client's drug product maker, and release to market, are for the client's own quality and regulatory people; the letter says so.

Is this a nitrosamine risk assessment template?

A template is filled in once and filed. Here the assessment is drafted in FDA's three steps from the map, the sums and the signed test plan, and any change control touching a solvent, reagent, vessel or water reopens it.

Bring one active's route
and its change controls.

Send one product's production instructions, its recovered-solvent log and the change controls since its last assessment; we will draw its crossings and work the limits.